Nasdaq · CIK 0001829635
RNAZ Transcode Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 32 d ago.
Transcode Therapeutics, Inc. (RNAZ) has 1 SEC Form 4 filing on file from 1 insider, the latest filed on Sep 11, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Transcode Therapeutics, Inc., scored.
Transactions
Every row filed, 1 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Thomas A Fitzgerald Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +185,000 | $0.00 | $0 | 185,000 | 32 d ago |
Questions about RNAZ
Answered from the filings on this page, as of the latest one.
Are insiders buying RNAZ?
No. In the last 90 days no insider at Transcode Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade RNAZ on the open market?
No open-market trade has been scored at Transcode Therapeutics, Inc.. The latest Form 4 on file was filed on Sep 11, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Transcode Therapeutics, Inc.?
1 person has filed a Form 4 at Transcode Therapeutics, Inc., among them Thomas A Fitzgerald (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.